Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Arnold Stephen Freedman, M.D.

Co-Author

This page shows the publications co-authored by Arnold Freedman and Caron Jacobson.
Connection Strength

4.309
  1. Is There a Best Initial Treatment for a New Patient With Low Grade Follicular Lymphoma. Curr Hematol Malig Rep. 2016 06; 11(3):218-23.
    View in: PubMed
    Score: 0.693
  2. Rethinking Prognosis and Therapy for Follicular Lymphoma. J Clin Oncol. 2015 Aug 10; 33(23):2489-91.
    View in: PubMed
    Score: 0.652
  3. Is observation dead in follicular lymphoma? Still appropriate. J Natl Compr Canc Netw. 2015 Mar; 13(3):367-70.
    View in: PubMed
    Score: 0.636
  4. One size does not fit all in follicular lymphoma. J Clin Oncol. 2013 Sep 20; 31(27):3307-8.
    View in: PubMed
    Score: 0.572
  5. First-line treatment of indolent lymphoma: axing CHOP? Lancet. 2013 Apr 06; 381(9873):1163-5.
    View in: PubMed
    Score: 0.552
  6. Early stage follicular lymphoma, current management and controversies. Curr Opin Oncol. 2012 Sep; 24(5):475-9.
    View in: PubMed
    Score: 0.535
  7. Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2013 Oct; 163(1):123-6.
    View in: PubMed
    Score: 0.141
  8. A prospective study of minimal residual disease in patients with diffuse large B-cell lymphoma using an Ig-NGS assay. Leuk Lymphoma. 2021 02; 62(2):478-481.
    View in: PubMed
    Score: 0.059
  9. Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Adv. 2020 03 10; 4(5):858-867.
    View in: PubMed
    Score: 0.056
  10. PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. Blood Adv. 2020 01 14; 4(1):122-126.
    View in: PubMed
    Score: 0.056
  11. Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia. Blood Adv. 2019 04 09; 3(7):1167-1174.
    View in: PubMed
    Score: 0.053
  12. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood. 2019 07 04; 134(1):22-29.
    View in: PubMed
    Score: 0.053
  13. Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. J Clin Oncol. 2017 Jan; 35(1):24-31.
    View in: PubMed
    Score: 0.045
  14. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183.
    View in: PubMed
    Score: 0.044
  15. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016 07 14; 128(2):195-203.
    View in: PubMed
    Score: 0.043
  16. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586.
    View in: PubMed
    Score: 0.043
  17. A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma. Br J Haematol. 2016 Apr; 173(1):89-95.
    View in: PubMed
    Score: 0.042
  18. Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era. Br J Haematol. 2013 Mar; 160(5):608-17.
    View in: PubMed
    Score: 0.034
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.